Baseline characteristics
| Variable . | Group 1: eligible for HSCT and related donor available . | Group 2: eligible for HSCT and no related donor available . | Group 3: not eligible for HSCT . | Total . | P . | |
|---|---|---|---|---|---|---|
| Group 1 vs group 2 . | Groups 1 and 2† vs group 3 . | |||||
| No. patients | 135 | 219 | 265 | 621* | ||
| Median age, y (range) | 39 (11-59) | 40 (14-58) | 61 (25-90) | 49 (11-90) | .800 | < .001 |
| Younger than 20 y, % | 3.7 | 4.1 | 0 | 2.3 | ||
| 20 to 40, % | 49.6 | 48.0 | 1.1 | 28.2 | ||
| Older than 40, % | 46.7 | 48.0 | 98.9 | 69.6 | ||
| Median prognostic score, %; | .371 | < .001 | ||||
| Low | 63.0 | 58.9 | 17.8 | 42.3 | ||
| Intermediate | 32.6 | 32.9 | 64.0 | 46.1 | ||
| High | 4.4 | 8.2 | 18.2 | 11.6 | ||
| Sex, % male | 60.7 | 62.1 | 56.6 | 59.6 | .798 | .192 |
| Fatigue, % | 44.4 | 47.5 | 51.5 | 48.6 | .577 | .203 |
| Symptoms due to organomegaly, % | 23.7 | 24.7 | 15.2 | 20.3 | .839 | .006 |
| Weight loss of more than 10%, % | 14.1 | 13.3 | 18.9 | 15.8 | .837 | .068 |
| Fever, % | 6.7 | 6.4 | 3.8 | 5.3 | .928 | .141 |
| Extramedullary manifestation, % | 0.7 | 2.7 | 2.7 | 2.3 | .259 | .570 |
| Median hemoglobin, g/dL (range) | 11.7 (6.8-16.5) | 11.8 (7.2-16.0) | 12.1 (5.1-18.8) | 12.0 (5.1-18.8) | .989 | .018 |
| Median WBC count, × 109/L (range) | 116 (4-560) | 122 (1-560) | 82 (4-650) | 101 (1-650) | .874 | < .001 |
| Median PB eosinophils, % (range) | 2 (0-15) | 2 (0-15) | 2 (0-51) | 2 (0-51) | .22 | .429 |
| Median PB basophils, % (range) | 3 (0-23) | 3 (0-22) | 3 (0-40) | 3 (0-40) | .188 | .96 |
| Median PB blasts, % (range) | 1 (0-15) | 1 (0-25) | 1 (0-33) | 1 (0-33) | .728 | .001 |
| Median BM blasts, % (range) | 3 (0-25) | 2 (0-17) | 2 (0-25) | 3 (0-25) | .358 | .891 |
| Median platelet count, × 109/L (range) | 409 (63-1880) | 373 (90-2343) | 371 (49-2694) | 381 (49-2694) | .858 | .633 |
| Variable . | Group 1: eligible for HSCT and related donor available . | Group 2: eligible for HSCT and no related donor available . | Group 3: not eligible for HSCT . | Total . | P . | |
|---|---|---|---|---|---|---|
| Group 1 vs group 2 . | Groups 1 and 2† vs group 3 . | |||||
| No. patients | 135 | 219 | 265 | 621* | ||
| Median age, y (range) | 39 (11-59) | 40 (14-58) | 61 (25-90) | 49 (11-90) | .800 | < .001 |
| Younger than 20 y, % | 3.7 | 4.1 | 0 | 2.3 | ||
| 20 to 40, % | 49.6 | 48.0 | 1.1 | 28.2 | ||
| Older than 40, % | 46.7 | 48.0 | 98.9 | 69.6 | ||
| Median prognostic score, %; | .371 | < .001 | ||||
| Low | 63.0 | 58.9 | 17.8 | 42.3 | ||
| Intermediate | 32.6 | 32.9 | 64.0 | 46.1 | ||
| High | 4.4 | 8.2 | 18.2 | 11.6 | ||
| Sex, % male | 60.7 | 62.1 | 56.6 | 59.6 | .798 | .192 |
| Fatigue, % | 44.4 | 47.5 | 51.5 | 48.6 | .577 | .203 |
| Symptoms due to organomegaly, % | 23.7 | 24.7 | 15.2 | 20.3 | .839 | .006 |
| Weight loss of more than 10%, % | 14.1 | 13.3 | 18.9 | 15.8 | .837 | .068 |
| Fever, % | 6.7 | 6.4 | 3.8 | 5.3 | .928 | .141 |
| Extramedullary manifestation, % | 0.7 | 2.7 | 2.7 | 2.3 | .259 | .570 |
| Median hemoglobin, g/dL (range) | 11.7 (6.8-16.5) | 11.8 (7.2-16.0) | 12.1 (5.1-18.8) | 12.0 (5.1-18.8) | .989 | .018 |
| Median WBC count, × 109/L (range) | 116 (4-560) | 122 (1-560) | 82 (4-650) | 101 (1-650) | .874 | < .001 |
| Median PB eosinophils, % (range) | 2 (0-15) | 2 (0-15) | 2 (0-51) | 2 (0-51) | .22 | .429 |
| Median PB basophils, % (range) | 3 (0-23) | 3 (0-22) | 3 (0-40) | 3 (0-40) | .188 | .96 |
| Median PB blasts, % (range) | 1 (0-15) | 1 (0-25) | 1 (0-33) | 1 (0-33) | .728 | .001 |
| Median BM blasts, % (range) | 3 (0-25) | 2 (0-17) | 2 (0-25) | 3 (0-25) | .358 | .891 |
| Median platelet count, × 109/L (range) | 409 (63-1880) | 373 (90-2343) | 371 (49-2694) | 381 (49-2694) | .858 | .633 |
PB indicates peripheral blood; BM, bone marrow.
Including 2 patients eligible for HSCT but with missing data on availability of related donor. These patients are not part of groups 1, 2, or 3.
The 2 eligible patients with missing data on availability of related donor are added to groups 1 and 2 for comparison with group 3.